GSK Quote, Financials, Valuation and Earnings

Merck & has a net margin of -0.72% compared to GSK PLC's net margin of 18.95%. GSK PLC's return on equity of 18.89% beat Merck &'s return on equity of 29.26%.

GSK PLC has a consensus price target of $42.93, signalling upside risk potential of 32.46%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that GSK PLC has higher upside potential than Merck &, analysts believe GSK PLC is more attractive than Merck &.

GSK PLC has a beta of 0.657, which suggesting that the stock is 34.349% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

GSK PLC has a quarterly dividend of $0.39 per share corresponding to a yield of 4.6%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. GSK PLC pays 45.6% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

GSK PLC quarterly revenues are $10.4B, which are smaller than Merck & quarterly revenues of $16.7B. GSK PLC's net income of -$75.5M is lower than Merck &'s net income of $3.2B. Notably, GSK PLC's price-to-earnings ratio is 22.12x while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.77x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -0.72% compared to GSK PLC's net margin of 0.7%. GSK PLC's return on equity of 18.89% beat Moderna's return on equity of -17.44%.

GSK PLC has a consensus price target of $42.93, signalling upside risk potential of 32.46%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Moderna has higher upside potential than GSK PLC, analysts believe Moderna is more attractive than GSK PLC.

GSK PLC has a beta of 0.657, which suggesting that the stock is 34.349% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

GSK PLC has a quarterly dividend of $0.39 per share corresponding to a yield of 4.6%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 45.6% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Moderna quarterly revenues of $1.9B. GSK PLC's net income of -$75.5M is lower than Moderna's net income of $13M. Notably, GSK PLC's price-to-earnings ratio is 22.12x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.77x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -0.72% compared to GSK PLC's net margin of 25.23%. GSK PLC's return on equity of 18.89% beat Pfizer's return on equity of 4.63%.

GSK PLC has a consensus price target of $42.93, signalling upside risk potential of 32.46%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that GSK PLC has higher upside potential than Pfizer, analysts believe GSK PLC is more attractive than Pfizer.

GSK PLC has a beta of 0.657, which suggesting that the stock is 34.349% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

GSK PLC has a quarterly dividend of $0.39 per share corresponding to a yield of 4.6%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. GSK PLC pays 45.6% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

GSK PLC quarterly revenues are $10.4B, which are smaller than Pfizer quarterly revenues of $17.7B. GSK PLC's net income of -$75.5M is lower than Pfizer's net income of $4.5B. Notably, GSK PLC's price-to-earnings ratio is 22.12x while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.77x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -0.72% compared to GSK PLC's net margin of 19.88%. GSK PLC's return on equity of 18.89% beat Sanofi SA's return on equity of 5.8%.

GSK PLC has a consensus price target of $42.93, signalling upside risk potential of 32.46%. On the other hand Sanofi SA has an analysts' consensus of $63.06 which suggests that it could grow by 30.59%. Given that GSK PLC has higher upside potential than Sanofi SA, analysts believe GSK PLC is more attractive than Sanofi SA.

GSK PLC has a beta of 0.657, which suggesting that the stock is 34.349% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.492%.

GSK PLC has a quarterly dividend of $0.39 per share corresponding to a yield of 4.6%. Sanofi SA offers a yield of 8.15% to investors and pays a quarterly dividend of $2.04 per share. GSK PLC pays 45.6% of its earnings as a dividend. Sanofi SA pays out 82.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are smaller than Sanofi SA quarterly revenues of $15.6B. GSK PLC's net income of -$75.5M is lower than Sanofi SA's net income of $3.1B. Notably, GSK PLC's price-to-earnings ratio is 22.12x while Sanofi SA's PE ratio is 24.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.77x versus 2.28x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.